, Volume 41, Issue 1, pp 135–144

Targets for antibiotic and healthcare resource stewardship in inpatient community-acquired pneumonia: a comparison of management practices with National Guideline Recommendations

  • T. C. Jenkins
  • S. A. Stella
  • L. Cervantes
  • B. C. Knepper
  • A. L. Sabel
  • C. S. Price
  • L. Shockley
  • M. E. Hanley
  • P. S. Mehler
  • W. J. Burman
Clinical and Epidemiological Study



Community-acquired pneumonia (CAP) is the most common infection leading to hospitalization in the USA. The objective of this study was to evaluate management practices for inpatient CAP in relation to Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines to identify opportunities for antibiotic and health care resource stewardship.


This was a retrospective cohort study of adults hospitalized for CAP at a single institution from 15 April 2008 to 31 May 2009.


Of the 209 patients with CAP who presented to Denver Health Medical Center during the study period and were hospitalized, 166 (79 %) and 43 (21 %) were admitted to a medical ward and the intensive care unit (ICU), respectively. Sixty-one (29 %) patients were candidates for outpatient therapy per IDSA/ATS guidance with a CURB-65 score of 0 or 1 and absence of hypoxemia. Sputum cultures were ordered for 110 specimens; however, an evaluable sample was obtained in only 49 (45 %) cases. Median time from antibiotic initiation to specimen collection was 11 [interquartile range (IQR) 6–19] h, and a potential pathogen was identified in only 18 (16 %) cultures. Blood cultures were routinely obtained for both non-ICU (81 %) and ICU (95 %) cases, but 15 of 36 (42 %) positive cultures were false-positive results. The most common antibiotic regimen was ceftriaxone + azithromycin (182, 87 % cases). Discordant with IDSA/ATS recommendations, oral step-down therapy consisted of a new antibiotic class in 120 (66 %), most commonly levofloxacin (101, 55 %). Treatment durations were typically longer than suggested with a median of 10 (IQR 8–12) days.


In this cohort of patients hospitalized for CAP, management was frequently inconsistent with IDSA/ATS guideline recommendations, revealing potential targets to reduce unnecessary antibiotic and healthcare resource utilization.


Pneumonia Community-acquired pneumonia Guidelines Infectious Diseases Society of America Antimicrobial stewardship Streptococcus pneumoniae Fluoroquinolones 


  1. 1.
    Hall MJ, DeFrances CJ, Williams SN, et al. National Hospital Discharge Survey: 2007 summary. Natl Health Stat Report. 2010;1–20, 24.Google Scholar
  2. 2.
    Bodenheimer T, Fernandez A. High and rising health care costs. Part 4: can costs be controlled while preserving quality? Ann Intern Med. 2005;143:26–31.PubMedGoogle Scholar
  3. 3.
    Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med. 2009;169:1515–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Carratala J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med. 2012;172:922–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Avdic E, Cushinotto LA, Hughes AH, et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis. 2012;54:1581–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Mansouri MD, Cadle RM, Agbahiwe SO, et al. Impact of an antibiotic restriction program on antibiotic utilization in the treatment of community-acquired pneumonia in a Veterans Affairs Medical Center. Infection. 2011;39:53–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. JAMA. 2000;283:749–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Jenkins TC, Sakai J, Knepper BC, et al. Risk factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia. Acad Emerg Med. 2012;19:703–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Gabow P, Eisert S, Wright R. Denver Health: a model for the integration of a public hospital and community health centers. Ann Intern Med. 2003;138:143–9.PubMedGoogle Scholar
  10. 10.
    The Joint Commission Specifications Manual for National Hospital Inpatient Quality Measures v4.1. Available at: Accessed 4 Sept 2012.
  11. 11.
    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.Google Scholar
  13. 13.
    Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382PubMedCrossRefGoogle Scholar
  14. 14.
    el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332:1355.CrossRefGoogle Scholar
  15. 15.
    McCabe C, Kirchner C, Zhang H, et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med. 2009;169:1525–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159:2449–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Garcia-Vazquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med. 2004;164:1807–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Sanz F, Restrepo MI, Fernandez E, et al. Hypoxemia adds to the CURB-65 pneumonia severity score in hospitalized patients with mild pneumonia. Respir Care. 2011;56:612–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Arnold FW, Ramirez JA, McDonald LC, et al. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest. 2003;124:121–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Beall DP, Scott WW, Jr., Kuhlman JE, et al. Utilization of computed tomography in patients hospitalized with community-acquired pneumonia. MD Med J. 1998;47:182–7.Google Scholar
  21. 21.
    Katz DS, Leung AN. Radiology of pneumonia. Clin Chest Med. 1999;20:549–62.PubMedCrossRefGoogle Scholar
  22. 22.
    Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169:2078–86.PubMedCrossRefGoogle Scholar
  23. 23.
    Afshar N, Tabas J, Afshar K, et al. Blood cultures for community-acquired pneumonia: are they worthy of two quality measures? A systematic review. J Hosp Med. 2009;4:112–23.PubMedCrossRefGoogle Scholar
  24. 24.
    Walls RM, Resnick J. The joint commission on accreditation of healthcare organizations and center for medicare and medicaid services community-acquired pneumonia initiative: what went wrong? Ann Emerg Med. 2005;46:409–11.PubMedCrossRefGoogle Scholar
  25. 25.
    Metersky ML, Ma A, Bratzler DW, et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med. 2004;169:342–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Alahmadi YM, Aldeyab MA, McElnay JC, et al. Clinical and economic impact of contaminated blood cultures within the hospital setting. J Hosp Infect. 2011;77:233–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Plouffe JF, McNally C, File TM Jr. Value of noninvasive studies in community-acquired pneumonia. Infect Dis Clin North Am. 1998;12:689–99 (ix).PubMedCrossRefGoogle Scholar
  28. 28.
    Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis. 2012;54:1126–33.PubMedCrossRefGoogle Scholar
  29. 29.
    Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008;121:876–84.PubMedCrossRefGoogle Scholar
  30. 30.
    MacDougall C, Powell JP, Johnson CK, et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005;41:435–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Adam HJ, Hoban DJ, Gin AS, et al. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997–2006. Int J Antimicrob Agents. 2009;34:82–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53:42–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Kallen AJ, Thompson A, Ristaino P, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol. 2009;30:264–72.PubMedCrossRefGoogle Scholar
  34. 34.
    Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60.PubMedCrossRefGoogle Scholar
  35. 35.
    Bernardo J, Yew WW. How are we creating fluoroquinolone-resistant tuberculosis? Am J Respir Crit Care Med. 2009;180:288–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Chen TC, Lu PL, Lin CY, et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011;15:e211–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med. 2004;3:329–36.PubMedCrossRefGoogle Scholar
  38. 38.
    Wong-Beringer A, Nguyen LH, Lee M, et al. An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse. Pharmacotherapy. 2009;29:736–43.PubMedCrossRefGoogle Scholar
  39. 39.
    Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis. 2011;52:1232–40.PubMedCrossRefGoogle Scholar
  40. 40.
    Pakyz AL, MacDougall C, Oinonen M, et al. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med. 2008;168:2254–60.PubMedCrossRefGoogle Scholar
  41. 41.
    Polk RE, Hohmann SF, Medvedev S, et al. Benchmarking risk-adjusted adult antibacterial drug use in 70 US academic medical center hospitals. Clin Infect Dis. 2011;53:1100–10.PubMedCrossRefGoogle Scholar
  42. 42.
    Norrby SR. Short-term treatment of uncomplicated lower urinary tract infections in women. Rev Infect Dis. 1990;12:458–67.PubMedCrossRefGoogle Scholar
  43. 43.
    Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect. 2011;17:E1–59.PubMedCrossRefGoogle Scholar
  44. 44.
    Bartlett JG, Rosenblatt JE, Finegold SM. Percutaneous transtracheal aspiration in the diagnosis of anaerobic pulmonary infection. Ann Intern Med. 1973;79:535–40.PubMedGoogle Scholar
  45. 45.
    Ries K, Levison ME, Kaye D. Transtracheal aspiration in pulmonary infection. Arch Intern Med. 1974;133:453–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • T. C. Jenkins
    • 1
    • 2
    • 6
    • 7
  • S. A. Stella
    • 1
    • 6
  • L. Cervantes
    • 1
    • 6
  • B. C. Knepper
    • 3
  • A. L. Sabel
    • 3
    • 10
  • C. S. Price
    • 1
    • 2
    • 6
    • 7
  • L. Shockley
    • 4
    • 8
  • M. E. Hanley
    • 1
    • 5
    • 6
    • 9
  • P. S. Mehler
    • 1
    • 3
    • 6
  • W. J. Burman
    • 1
    • 2
    • 6
    • 7
  1. 1.Department of MedicineDenver Health Medical CenterDenverUSA
  2. 2.Division of Infectious DiseasesDenver Health Medical CenterDenverUSA
  3. 3.Department of Patient Safety and QualityDenver Health Medical CenterDenverUSA
  4. 4.Department of Emergency MedicineDenver Health Medical CenterDenverUSA
  5. 5.Division of Pulmonary and Critical CareDenver Health Medical CenterDenverUSA
  6. 6.Department of MedicineUniversity of Colorado DenverAuroraUSA
  7. 7.Division of Infectious DiseasesUniversity of Colorado DenverAuroraUSA
  8. 8.Department of Emergency MedicineUniversity of Colorado DenverAuroraUSA
  9. 9.Division of Pulmonary and Critical CareUniversity of Colorado DenverAuroraUSA
  10. 10.Department of Biostatistics and InformaticsColorado School of Public HealthAuroraUSA

Personalised recommendations